ArticleFrontiers in neuroscience2014
Activation of endogenous neural stem cells for multiple sclerosis therapy.
Article in Frontiers in neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Single-Cell Analysis of L-Myc Expressing Neural Stem Cells and Their Extracellular Vesicles Revealed Distinct Progenitor Populations With Neurogenic Potential.Journal of extracellular biology · 2025Article
- Neural stem cells in adult neurogenesis and their therapeutic applications in neurodegenerative disorders: a concise review.Frontiers in molecular medicine · 2025Review
- Neuroprotective potential of intranasally delivered L-myc immortalized human neural stem cells in female rats after a controlled cortical impact injury.Scientific reports · 2023Article
- Influence of hormones in multiple sclerosis: focus on the most important hormones.Metabolic brain disease · 2023Review
- Editorial: Activation and stimulation of endogenous neural stem/progenitor cells in multiple sclerosis and other neurodegenerative diseases.Frontiers in cellular neuroscience · 2023Article
- The role of neural stem cells in regulating glial scar formation and repair.Cell and tissue research · 2022Review
- A Two-Stage Process for Differentiation of Wharton's Jelly-Derived Mesenchymal Stem Cells into Neuronal-like Cells.Stem cells international · 2021Article
- Thyroid Hormone and Neural Stem Cells: Repair Potential Following Brain and Spinal Cord Injury.Frontiers in neuroscience · 2020Review
- Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- The role of oligodendrocytes and their progenitors on neural interface technology: A novel perspective on tissue regeneration and repair.Biomaterials · 2018Review
- Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimer's Disease.BioMed research international · 2018Review
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System.Frontiers in cell and developmental biology · 2017Review
- Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies.Neuropharmacology · 2016Review
- Thyroid Hormone Potentially Benefits Multiple Sclerosis via Facilitating Remyelination.Molecular neurobiology · 2016Review
- Are Modular Activations Altered in Lower Limb Muscles of Persons with Multiple Sclerosis during Walking? Evidence from Muscle Synergies and Biomechanical Analysis.Frontiers in human neuroscience · 2016Article
- Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, leading to severe neurological deficits. Current MS treatment regimens, consist of immunomodulatory agents aiming to reduce the rate of relapses. However, these agents are usually insufficient to treat chronic neurological disability. A promising perspective for future therapy of MS is the regeneration of lesions with replacement of the damaged oligodendrocytes or neurons. Therapies targeting to the enhancement of endogenous remyelination, aim to promote the activation of either the parenchymal oligodendrocyte progenitor cells or the subventricular zone-derived neural stem cells (NSCs). Less studied but highly potent, is the strategy of neuronal regeneration with endogenous NSCs that although being linked to numerous limitations, is anticipated to ameliorate cognitive disability in MS. Focusing on the forebrain, this review highlights the role of NSCs in the regeneration of MS lesions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.